Format

Send to

Choose Destination
Clin Cancer Res. 2010 Aug 15;16(16):4074-6. doi: 10.1158/1078-0432.CCR-10-1438. Epub 2010 Jun 29.

NF1 inactivation revs up Ras in adult acute myelogenous leukemia.

Author information

1
Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

Abstract

Mutations in the Ras pathway are common in myeloid malignancies. NF1, a tumor suppressor and negative regulator of Ras, is inactivated in a subset of adult acute myelogenous leukemia (AML) cases. Loss of NF1 function sensitizes cells to inhibition of mammalian target of rapamycin (mTOR), a downstream effector of Ras activation, highlighting a potential therapeutic opportunity for some AML patients.

PMID:
20587590
DOI:
10.1158/1078-0432.CCR-10-1438
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center